Turkish USIQ: Validity & Reliability
ConditionOveractive Bladder
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-65
SponsorIzmir Democracy University
About this trial
The Urgency, Severity, and Impact Questionnaire (USIQ) assesses urinary urgency independently of incontinence, measuring both symptom severity and its impact on quality of life. While validated in English and Hebrew populations, a Turkish version has not yet been developed. This study aims to adapt USIQ for the Turkish population and evaluate its psychometric properties, providing a standardized, culturally relevant tool for clinical and research use.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Women aged 18-65 years
Able to read and write in Turkish
Diagnosed with overactive bladder (OAB) presenting with urgency (either wet or dry type)
Willing to sign the informed consent form after being informed about the study
Disqualifiers
Urinary tract infection symptoms or an active infection diagnosis within the past month
Neurological conditions causing neurogenic bladder such as multiple sclerosis, Parkinson's disease, stroke, or spinal cord injury
Cognitive impairment preventing comprehension and completion of the questionnaires
Post-void residual urine volume (PVR) exceeding 150 mL
Trial population
For your study, based on the information you've provided, participants are volunteer women attending the clinic who meet your inclusion criteria. This means the sample is not randomly selected from the general population, so it is a non-probability sample.
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
Observational Cohort
Other interventionWomen diagnosed with Overactive Bladder (OAB) attending the Gynecology and Oncology Clinic at Buca Seyfi Demirsoy Training and Research Hospital who meet inclusion and exclusion criteria. Participants will complete demographic and clinical questionnaires, including USIQ, IIQ-7, UDI-6, and OAB-q. Test-retest reliability will be assessed in a subgroup after 14 days.
Treatment groups
130 Participants
are divided into 1 treatment groupGroup A: Observational Cohort1 intervention
Trial outcomes
Primary outcomes
1
Urgency, Severity and Impact Questionnaire (USIQ)
The USIQ, developed by Lowenstein et al. in 2009, is a patient-reported instrument assessing the severity of urgency symptoms and their impact on quality of life. It consists of two subscales: USIQ-S (Symptom Severity) with 5 items measuring urgency complaints, and USIQ-QOL (Quality of Life) with 8 items assessing the effect on daily life, totaling 13 items. Responses are scored 0-4, with an additional "Don't know"/"Not applicable" option excluded from scoring. USIQ-S and USIQ-QOL scores are calculated by averaging item scores and multiplying by 25, yielding a 0-100 scale. Higher scores indicate more severe urgency symptoms and greater impact on quality of life. Cronbach's alpha values are 0.85 for USIQ-S and 0.90 for USIQ-QOL.
Time frame
At Baseline2
Incontinence Impact Questionnaire-Short Form (IIQ-7)
The IIQ-7, developed as a short form in 1995, evaluates the impact of urinary incontinence on women's daily quality of life. It includes 7 items addressing household chores, physical activity, social activity, travel, and emotional well-being. Each item is scored 0-3: 'Not at all' (0), 'Slightly' (1), 'Moderately' (2), and 'Greatly' (3). Total scores are summed and standardized to a 0-100 scale, with higher scores indicating greater negative impact on quality of life. Internal consistency (Cronbach's alpha) ranges from 0.87 to 0.90. The Turkish version was validated by Cam in 2007.
Time frame
At baseline3
Urogenital Distress Inventory-Short Form (UDI-6)
The UDI-6 Short Form, developed in 1995, assesses urogenital symptoms including stress urinary incontinence, urgency incontinence, frequency, small amounts of urine leakage, voiding phase complaints, and pelvic/perineal discomfort. It does not directly assess the impact on quality of life. Each item is scored 0-3 to indicate the distress caused: 'Not at all' (0), 'A little bit' (1), 'Moderately' (2), and 'Greatly' (3). Item scores are summed and standardized to a 0-100 scale, with higher scores reflecting greater symptom distress. Internal consistency (Cronbach's alpha) for subscales ranges from 0.48 to 0.77. The Turkish version was validated by Cam in 2007.
Time frame
At baseline4
International Consultation on Incontinence Modular Questionnaire-Overactive Bladder Quality of Life Questionnaire (ICIQ-OABqol / OAB-q)
The OAB-q, developed in 2002, measures symptom bother and disease-specific quality of life in patients with overactive bladder, applicable to both incontinent and continent patients. The questionnaire has 33 items: 8 assess symptom bother and 25 assess quality of life across coping (8 items), concern (7 items), social interaction (5 items), and sleep (5 items). All items use a 6-point Likert scale. Symptom bother items are scored from 1 ('Not at all') to 6 ('A very great deal'), while quality of life items are scored from 1 ('None of the time') to 6 ('All of the time'). Raw scores are standardized to a 0-100 scale, with higher symptom bother scores indicating increased symptom severity, and higher quality of life scores indicating better quality of life. Internal consistency (Cronbach's alpha) ranges from 0.86 to 0.94. The Turkish version was validated in 2008.
Time frame
At baselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: